Co-ordinated EU GMP Inspection Guidelines: What You Need to Know
New EU GMP inspection guidelines take effect in September 2026. Here is what you need to know about joint inspections, planning, and reporting.
Co-ordinated EU GMP inspection guidelines are changing as the European Medicines Agency (EMA) introduces Version 3 of its procedure for centrally authorised products (CAPs).
The updated framework takes effect on 10 September 2026 and places sharper emphasis on early planning, clearer authority roles, joint inspections, and consistent reporting.
What Has Changed in New EU GMP Inspection Guidelines?
The EMA adopted Version 3 of “Co-ordinating GMP inspections for centrally authorised products” in April 2026. It supersedes Version 2.0, adopted in January 2025.
The EMA describes the changes as minor amendments, focused mainly on clarifying when an inspection can proceed without a Supporting Authority, alongside editorial updates.
However, that description understates the practical importance for manufacturers.
The procedure covers GMP inspections performed by EEA Member State Competent Authorities at the request of the EMA.
These inspections can support assessment of centralised marketing authorisation applications, variations, line extensions, and ongoing GMP compliance. The central principle remains co-ordination.
EMA-managed inspections use IRIS, while inspection reports must follow the Union format, address issues raised during regulatory assessment, and be finalised within the deadline set in the inspection request.
The EMA also reviews the scientific quality and completeness of reports and can return reports that are deficient or incomplete.
For pharmaceutical companies, this means inspection readiness is not simply a site-level activity, but sits within a wider regulatory process involving the applicant, manufacturer, EMA, Supervisory Authorities, inspectors, and, where required, additional authorities.
How AI Is Opening New Opportunities in Fertility Care for Pharma
"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.
Joint EU GMP Inspections Become More Structured
One of the most important aspects of the revised procedure is the EMA’s active promotion of joint inspections.
The framework expects EU/EEA inspectorates to cooperate with each other and encourages use of the EudraGMDP planning module to identify suitable opportunities for joint inspections of third-country sites.
The aim is not only to share workload, but is also to improve consistency, continuity, and knowledge sharing across inspectorates.
The revised procedure sets out how Leading and Supporting Authorities should be selected.
The Leading Authority is normally the Supervisory Authority for one or more products included in the inspection. Selection can also take account of the number of products under an authority’s supervision and previous inspection history.
A Supporting Authority may be another Supervisory Authority connected to products manufactured or tested at the same site.
This creates a more coordinated model for complex global manufacturing networks.
A single site can support multiple products, marketing authorisations, manufacturing activities, and regulatory relationships. Joint inspection planning gives authorities a mechanism to bring relevant expertise together rather than treating each product relationship in isolation.
However, the updated procedure also recognises that two authorities are not always necessary. Smaller manufacturing sites, certain quality control laboratories, or sites with only one relevant Supervisory Authority may be inspected by one authority acting in both roles.
This is an important clarification that ensures inspection structure matches the site, products, complexity, and available expertise.
Early Planning Is a Regulatory Advantage
Timing is one of the strongest operational messages in the new procedure.
For routine re-inspections of third-country sites, Leading and Supporting Authorities should be agreed early. The procedure states that inspections, including the authority roles, should be agreed around 12 months before the reporting deadline, and at least nine months in advance.
Pre-approval and for-cause inspections operate under tighter timelines. For CAP applications, pre-approval inspections generally occur within the assessment window between Day 80 and Day 121.
The procedure therefore expects team composition to be determined as early as possible, with volunteers for a call for expression of interest generally provided within 14 days unless another timeframe applies.
For manufacturers, this changes the meaning of inspection readiness.
A site cannot just assume that preparation starts when inspectors announce their visit. The applicant must identify proposed active substance and finished product manufacturers, relevant batch-release sites, and contact points in the pre-submission notification.
Where necessary, the applicant should also provide a flowchart showing how different sites contribute to the manufacturing network.
Every site included in the application needs to be inspection-ready from submission and compliant with EU GMP or an equivalent standard.
That requirement makes manufacturing network visibility a vital regulatory capability.
Inspection Data and Reporting Matter More Than Ever
The inspection itself is only one part of the process. The revised procedure reinforces the importance of the evidence produced around it.
Inspectors must prepare reports in English and use the format established by the Compilation of Union Procedures.
Reports must address relevant questions from the Rapporteur or Co-Rapporteur and issues identified by CHMP, CVMP, or the EMA, including reported problems and quality defects.
The EMA then reviews the submitted report for adherence to the procedure, scientific content, and overall quality.
If the report does not meet the required standard, the EMA can return it to the responsible authorities with reasons and a proposed deadline for revision, re-inspection, or another remedial action.
Therefore, inspection readiness should include the ability to provide accurate, coherent, and traceable information quickly.
Site Master File content, dossier information, manufacturing arrangements, quality records, and responses to known issues all need to align.
The same principle extends into digital regulatory infrastructure.
The EMA coordinates inspections through IRIS, while EudraGMDP provides a shared European information database containing GMP certificates, non-compliance statements, manufacturing and import authorisations, and inspection planning information.
The EudraGMDP database is therefore important for any inspection administration. It forms part of the wider infrastructure through which GMP information is shared and made visible to regulators and, where appropriate, industry and the public.
The Same GMP Shift Beyond Europe
Pharmatica’s analysis of digital CMC regulatory submissions points to a wider regulatory direction occurring globally.
There is a need for greater collaboration, better-connected regulatory data, and less fragmented oversight across jurisdictions.
The U.S. is exploring a related shift from a different starting point. Our analysis of the Food and Drug Administration (FDA) PreCheck Pilot Program examines how earlier engagement between manufacturers and regulators could strengthen facility design, quality systems, and manufacturing readiness before traditional inspection points.
Together, these developments suggest that regulatory oversight is moving upstream, with earlier preparation, stronger information exchange, and greater manufacturing visibility becoming strategic capabilities rather than purely compliance activities.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
A Not So Very New Framework for Co-ordinated EU GMP Inspection
The revised procedure is not a wholesale rewrite of EU GMP inspection policy. Rather, it is a clarification of how a complex inspection system should operate.
Yet the strategic implications are material.
First, manufacturing organisations need earlier regulatory planning. Inspection readiness should be built into submission planning, site qualification, technology transfer, and lifecycle management rather than treated as a late-stage compliance project.
Secondally, global manufacturing networks need clearer ownership. When several authorities oversee different products at one site, companies need a precise view of responsibilities, inspection history, product scope, and site-level risks.
Additionally, joint inspections may increase the importance of consistency across the organisation. Different authorities can bring different expertise, but the manufacturer still needs one coherent evidence base. Conflicting explanations, fragmented records, or inconsistent process descriptions can create avoidable risk.
Lastly, and most importantly, data quality is now inseparable from inspection readiness. The EMA’s use of IRIS and EudraGMDP reflects a regulatory environment in which information must move between organisations, systems, and authorities without losing context.
The EMA’s wider Compilation of Union Procedures supports this harmonisation by providing common procedures and templates for inspections and information exchange.
This also connects with a wider manufacturing shift. Pharmatica’s analysis of continuous improvement in pharma manufacturing shows why inspections should be viewed as part of an ongoing quality system rather than isolated compliance events. Likewise, data integrity and ALCOA principles are increasingly relevant as manufacturing organisations depend on connected data, digital systems, and traceable decision-making.
The new framework reinforces what we already knew. Regulatory confidence depends not only on whether a site can pass an inspection, but on whether its processes, records, responsibilities, and data remain coherent throughout the product lifecycle.
Inspection readiness is an organisational capability.
At Pharmatica, we analyse how regulatory systems, manufacturing operations, and digital infrastructure are reshaping pharmaceutical compliance. Our Regulatory coverage connects policy changes with the operational decisions that determine inspection readiness, manufacturing resilience, and market access.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What are the new EU GMP inspection guidelines for centrally authorised products?
The latest EMA procedure is Version 3 of “Co-ordinating GMP inspections for centrally authorised products”. It was adopted in April 2026 and enters into force on 10 September 2026. It clarifies the coordination of inspections, including when a Supporting Authority may not be required.
What is a joint GMP inspection in the EU?
A joint GMP inspection involves cooperation between more than one competent authority when inspecting a manufacturing site. The revised EMA procedure actively promotes joint inspections, particularly for suitable third-country sites, to support cooperation, consistency, and knowledge sharing.
When should EU GMP inspection teams be agreed?
For routine re-inspections of third-country sites, the revised procedure states that inspection teams and Leading and Supporting Authorities should be agreed around 12 months before the reporting deadline, and at least nine months in advance. Pre-approval inspections follow tighter timelines.
What is the role of the Leading Authority in a GMP inspection?
The Leading Authority coordinates the inspection and is normally the Supervisory Authority for one or more products included in the inspection. It works with any Supporting Authority and ultimately has responsibility for issuing GMP certificates or statements of non-compliance and updating EudraGMDP.
How should pharmaceutical companies prepare for an EU GMP inspection?
Companies should ensure that sites named in a centralised marketing authorisation application are inspection-ready from submission. They should maintain accurate manufacturing information, site documentation, relevant dossier content, quality records, and clear ownership across the manufacturing network.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)